2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119592
    Cyclophostin 98%
    Cyclophostin is an acetylcholinesterase (AChE) inhibitor with IC50 values of 45, 0.76 and 1.3 nM for humans and two different insects, respectively.
    Cyclophostin
  • HY-119605
    DAA-1097 220551-79-1 98%
    DAA-1097 is an orally active and selective agonist for the peripheral benzodiazepine receptor (PBR). DAA-1097 has anxiolytic effects.
    DAA-1097
  • HY-119615
    Mezilamine 50335-55-2 98%
    Mezilamine is a potent antidopaminergic agent. Mezilamine induces a concentration dependent increase in the electrically stimulated overflow of 3H-noradrenaline from rat cortical slices, without affecting the basal overflow. Mezilamine acts as a presynaptic α-adrenoceptor antagonist and a postsynaptic α-adrenoceptor agonist.
    Mezilamine
  • HY-119638
    Oxiperomide 5322-53-2 98%
    Oxiperomide is an orally active dopamine-blocking agent.
    Oxiperomide
  • HY-119744
    BAY 38-7271 212188-60-8 98%
    BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist, with Kis of 1.85 nM and 5.96 nM for recombinant human CB1 receptor and CB2 receptor, respectively. BAY 38-7271 has strong neuroprotective properties.
    BAY 38-7271
  • HY-119765
    VU0366248 1243310-20-4 98%
    VU0366248 is a mGlu5 negative allosteric modulator.
    VU0366248
  • HY-119768
    (±)-BAK2-66 1301178-83-5 98%
    (±)-BAK2-66 is a selectivity dopamine D3 receptor antagonist with theKi values of 1nM and 960 nM for D3R and D2R, respectively. (±)-BAK2-66 can be used for study in animal models of addiction.
    (±)-BAK2-66
  • HY-119795
    Zometapine 51022-73-2 98%
    Zometapine (CI-781) is a pyrazolodiazepine derivative. Zometapine can be used in antidepressant research.
    Zometapine
  • HY-119804
    Licopyranocoumarin 117038-80-9 98%
    Licopyranocoumarin is an isoflavonoid that shows CYP3A4 inhibitory activity with an IC50 of 32 μM. Licopyranocoumarin has potent neuroprotective activities.
    Licopyranocoumarin
  • HY-119806
    TMPPAA 844900-50-1 98%
    TMPPAA is an allosteric agonist and positive allosteric modulator of the 5-HT3 receptor. TMPPAA enhances 5-HT-mediated 5-HT3AR signaling.
    TMPPAA
  • HY-119857
    AGK7 304896-21-7 98%
    AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease.
    AGK7
  • HY-119864
    Drinidene 53394-92-6
    Drinidene can be used for the research of pain disorders extracted from patent AU2018254530A1.
    Drinidene
  • HY-119886
    BMS-986169 1801151-08-5 98%
    BMS-986169 is an inhibitor of the glutamate N-methyl-D-aspartate 2B receptor (GluN2B). BMS-986169 has a high binding affinity for the allosteric regulatory site of the GluN2B subunit, with a Ki value of 4.03-6.3 nM. BMS-986169 can inhibit the function of GluN2B receptors in Xenopus oocytes, with an IC50 value of 24.1 nM. BMS-986169 can also inhibit the activity of the hERG channel, with an IC50 value of 28.4 μM. BMS-986169 can be used in research on treatment-resistant depression.
    BMS-986169
  • HY-119915
    Atrolactamide 2019-68-3 98%
    Atrolactamide (M-144) is a potent anticonvulsant. Atrolactamide can be used for the research of epilepsy.
    Atrolactamide
  • HY-119921
    Indatraline 86939-10-8 98%
    Indatraline (Lu 19005 free base) is a long-acting monoamine reuptake inhibitor that can be used in the research of neurological diseases.
    Indatraline
  • HY-119926
    13-Hydroxylupanine 15358-48-2 98%
    13-Hydroxylupanine (Hydroxylupanine) is the typical alkaloid profile of sweet lupins.13-Hydroxylupanine blocks ganglionic transmission, decreases cardiac contractility and contracts uterine smooth muscle.
    13-Hydroxylupanine
  • HY-119950
    ADCI 124070-15-1 98%
    ADCI, a noncompetitive NMDA antagonist, is a broad-spectrum anticonvulsant agent.
    ADCI
  • HY-119990
    Fotocaine 1612189-10-2 98%
    Fotocaine is a photochromic blocker of voltage-gated ion channels. Fotocaine is readily taken up by neurons in brain slices and enables optical control of action potential firing by switching between 350 and 450 nm light. Fotocaine can be used in analgesia research.
    Fotocaine
  • HY-120016
    RU 43044 136959-96-1 98%
    RU 43044 is a glucocorticoid receptor antagonist. RU 43044 shows an antidepressant-like effect, probably via an inhibition of enhanced prefrontal dopaminergic neurotransmission in these mouse models.
    RU 43044
  • HY-120017
    Befloxatone 134564-82-2 98%
    Befloxatone (MD-370503) is an orally active, selective and reversible inhibitor of Monoamine Oxidase A (MAO-A) (IC50=4 nM). Befloxatone increases the tissue level of monoamine, striatal dopamine and cortical norepinephrine. Befloxatone has antidepressant potential.
    Befloxatone
Cat. No. Product Name / Synonyms Application Reactivity